Achieve Life Sciences (ACHV) Change in Account Payables (2012 - 2026)
Achieve Life Sciences (ACHV) posted Change in Account Payables of -$53000.0 for Q1 2026, down 453.33% on a QoQ basis from $15000.0 in Q4 2025, and up 81.91% year-over-year from -$29135.1 in Q1 2025.
Achieve Life Sciences (ACHV) Change in Account Payables (2012 - 2026) Analysis & Trends
Achieve Life Sciences' Change in Account Payables history runs 15 years deep, the most recent figure standing at -$53000.0 for Q1 2026.
- Quarterly Change in Account Payables rose 81.91% year-over-year to -$53000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248000.0 (down 80.69% YoY) and the FY2025 annual result came in at $8000.0, down 99.4% from the prior year.
- Change in Account Payables was -$53000.0 for Q1 2026 at Achieve Life Sciences, down from $15000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.2 million in Q4 2022 and bottomed at -$702000.0 in Q2 2023.
- A 5-year average of $61411.8 and a median of -$20000.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables sank 394.96% — and 2024, when it surged 4795.0%.
- Achieve Life Sciences' Change in Account Payables stood at $1.2 million in 2022, then sank by 101.63% to -$20000.0 in 2023, then jumped by 4795.0% to $939000.0 in 2024, then sank by 98.4% to $15000.0 in 2025, then slumped by 453.33% to -$53000.0 in 2026.
- Business Quant data shows ACHV's Change in Account Payables at -$53000.0 in Q1 2026, $15000.0 in Q4 2025, and $725000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 16.86 Mn |
| 10 | Achieve Life Sciences | 326.16 Mn | 326.16 Mn | - | -53,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53,000.00 |
| Mar 31, 2026 | -53,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 725,000.00 |
| Sep 30, 2025 | 725,000.00 |
| Jun 30, 2025 | -439,000.00 |
| Jun 30, 2025 | -439,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Dec 31, 2024 | 939,000.00 |
| Dec 31, 2024 | 939,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Jun 30, 2024 | 177,000.00 |
| Jun 30, 2024 | 177,000.00 |
| Mar 31, 2024 | -245,000.00 |
| Mar 31, 2024 | -245,000.00 |
| Dec 31, 2023 | -20,000.00 |
| Dec 31, 2023 | -20,000.00 |